<DOC>
	<DOC>NCT02001233</DOC>
	<brief_summary>The purpose of this follow-up study is to evaluate the two-year efficacy, immunogenicity and safety of EV71 Vaccines in preventing Hand, Foot and Mouth disease caused by EV71 in a total 10,000 healthy infants volunteers aged from 6 to 35months old.</brief_summary>
	<brief_title>A Follow-up Study for a Phase III, Efficacy Trial in Inactivated Enterovirus Type 71 (EV71) Vaccine</brief_title>
	<detailed_description>The phase III, efficacy trial of inactivated vaccine (vero cell) against EV71 has completed on March 2013 in China. The data from the phase III study suggested that the inactivated EV71 vaccine had protection effects on healthy Chinese infants against Hand, Foot and Mouth disease caused by EV71 within one-year surveillance period, and had clinically acceptable safety and good one-year immune persistence. This study is the phase III, open-labelled, follow-up research, in order to evaluate the two-year efficacy, safety and immune persistence.</detailed_description>
	<mesh_term>Mouth Diseases</mesh_term>
	<mesh_term>Enterovirus Infections</mesh_term>
	<mesh_term>Foot-and-Mouth Disease</mesh_term>
	<mesh_term>Hand, Foot and Mouth Disease</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>All subjects vaccinated at least one injection of EV71 vaccine or the placebo in the phase III efficacy trial. subjects who refuse to continue in the study.</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>35 Months</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>EV71 vaccine</keyword>
	<keyword>EV71-associated HFMD</keyword>
	<keyword>efficacy</keyword>
	<keyword>safety</keyword>
	<keyword>immune persistence</keyword>
</DOC>